Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -3352.93x is 10013% below its 5-year average of -33.16x, around the middle of its 5-year range (-8098.87x–-9.31x).
As of the fiscal period ended Tuesday, June 30, 2026. 26.44% above its 12-month average of -4558.31x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -3352.93x.
INTEREST COVERAGE RATIO
-3352.93x
INTEREST COVERAGE RATIO AVG TTM
-4558.31x
INTEREST COVERAGE RATIO AVG 3Y
-1931.24x
INTEREST COVERAGE RATIO AVG 5Y
-33.16x
INTEREST COVERAGE RATIO AVG 10Y
-11.88x
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+26.44%
CURRENT VS 3Y AVG
-73.62%
CURRENT VS 5Y AVG
-10012.77%
CURRENT VS 10Y AVG
-28129.79%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.31x
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
-53036.70%
vs the sector median at left
Skye Bioscience, Inc.
Market Cap
$7.29M
Interest Coverage Ratio
-3352.93x
TTM Avg
-4558.31x
3Y Avg
-1931.24x
5Y Avg
-33.16x
Market Cap
$7.25M
Interest Coverage Ratio
-924.78x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.13M
Interest Coverage Ratio
-185.05x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.13M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.55M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.02M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.95M
Interest Coverage Ratio
-10117.00x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | $7.29M | -3352.93x | -4558.31x | -1931.24x | -33.16x |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -924.78x | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.21M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.13M | -185.05x | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.07M | -11.95x | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.55M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.02M | N/A | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $6.95M | -10117.00x | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.94M | N/A | N/A | N/A | N/A |
Interest Coverage
-3352.9x
Debt/Equity
N/A
Current Ratio
0.95
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -3352.93x |
| 2026-03-31 | -5763.70x |
| 2025-03-31 | -8098.87x |
| 2024-09-30 | -17.07x |
| 2024-06-30 | -18.68x |
| 2024-03-31 | -14.08x |
| 2023-12-31 | -9.50x |
| 2023-09-30 | -91.06x |
| 2023-06-30 | -15.25x |
| 2023-03-31 | -168.52x |
| 2022-12-31 | -54.67x |
| 2022-09-30 | -13.83x |
| 2022-06-30 | -15.68x |
| 2022-03-31 | -14.51x |
| 2021-12-31 | -12.38x |
| 2021-09-30 | -9.31x |
| 2021-06-30 | -9.63x |
| 2021-03-31 | -9.40x |
| 2020-12-31 | -7.10x |
| 2020-09-30 | -8.42x |
| 2020-06-30 | -7.11x |
| 2020-03-31 | -13.29x |
| 2019-12-31 | -6.38x |
| 2019-09-30 | -4.98x |
| 2019-06-30 | -6.02x |
| 2019-03-31 | -13.05x |
| 2018-12-31 | -23.05x |
| 2018-09-30 | -1.00x |
| 2018-03-31 | -33.18x |
| 2016-12-31 | -4.38x |
| 2016-09-30 | -9.65x |
| 2016-03-31 | -2.63x |
| 2015-09-30 | -3.13x |
| 2015-06-30 | -1.94x |
| 2014-06-30 | 5.22x |
| 2014-04-30 | -43.75x |
| 2014-01-31 | -3.00x |
| 2013-10-31 | -8.40x |
| 2013-07-31 | 1.12x |
| 2013-04-30 | 5.57x |
| 2013-01-31 | -29.08x |
